MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Cost of Revenue 2011-2026 | OPK
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 495 M | 545 M | 716 M | - | - | - | - | - | 564 M | 193 M | 48 M | 48.9 M | 27.9 M | 17.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 716 M | 17.2 M | 295 M |
Quarterly Cost of Revenue OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107 M | 107 M | - | 131 M | 132 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.4 M | 10.3 M | - | 11.1 M | 12.6 M | 12.4 M | - | 12 M | 13.1 M | 11.8 M | - | 7.49 M | 6.55 M | 4.99 M | - | 4.02 M | 4.89 M | 4.18 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | 4.02 M | 33.7 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
4.81 M | $ 2.16 | 1.41 % | $ 4.96 M |  USA |
 |
Bioventus
BVS
|
180 M | $ 9.15 | 1.67 % | $ 610 M | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
176 M | $ 16.34 | 0.06 % | $ 494 M | USA |
 |
Guardant Health
GH
|
349 M | $ 83.59 | -1.54 % | $ 10.5 B | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 101.28 | 0.93 % | $ 8.35 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.64 B | $ 570.21 | -1.43 % | $ 45.9 B | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 74.24 | -1.97 % | $ 5.01 B | USA |
 |
Co-Diagnostics
CODX
|
4.18 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.61 | -1.07 % | $ 427 M | USA |
 |
Natera
NTRA
|
158 M | $ 194.52 | -2.78 % | $ 19.1 B | USA |
 |
IQVIA Holdings
IQV
|
10.9 B | $ 166.09 | -0.52 % | $ 28.6 B | USA |
 |
Organovo Holdings
ONVO
|
5 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
3.32 M | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
114 M | $ 1.39 | - | $ 417 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
15.3 M | $ 1.18 | -19.18 % | $ 6.43 M | USA |
 |
Interpace Biosciences
IDXG
|
17 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 125.98 | 1.77 % | $ 20 B | USA |
 |
Personalis
PSNL
|
57.8 M | $ 7.78 | 2.23 % | $ 461 M | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
Precipio
PRPO
|
9.18 M | $ 26.6 | -1.23 % | $ 34.5 M | USA |
 |
RadNet
RDNT
|
1 B | $ 59.87 | -3.03 % | $ 4.5 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 266.12 | 0.64 % | $ 22.1 B | USA |
 |
ENDRA Life Sciences
NDRA
|
173 K | $ 3.46 | -0.57 % | $ 1.86 M | USA |
 |
NeoGenomics
NEO
|
413 M | $ 7.86 | -2.96 % | $ 1.01 B | USA |
 |
Renalytix AI plc
RNLX
|
2.13 M | - | 5.66 % | $ 22.7 M |  Britain |